- Monday, October 2, 2023
8:10 AM – 8:17 AM PT
134 - Cell-Free DNA Fragmentomics for Early Detection of Malignant Transformation in NF1 Patients Harboring Plexiform NeurofibromasLocation: Room 4Presenter: – Washington University in St. Louis
Aadel Chaudhuri, MD, PhD – Washington University in St. Louis ### 524821###Presenter###Disclosures: Employment: Washington University in St. Louis:Assistant Professor:Employee | Compensation: Roche: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria, Travel Expenses, Compensation Payment-End Date: Present ;Tempus Labs: Consultant, Grant Research Funding, Compensation Payment-End Date: Present ;Geneoscopy: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Remuneration Other-End Date: Present ;Illumina: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: Present ;Daiichi Sankyo: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: Present ;AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: Present ;AlphaSights: Consultant, Compensation Payment-End Date: Present ;DeciBio: Consultant, Compensation Payment-End Date: Present ;Guidepoint: Consultant, Compensation Payment-End Date: Present ;Dava Oncology: Education Meeting Faculty, Honoraria-End Date: 8/2021 ;NuProbe: Consultant, Compensation Payment-End Date: 11/2021 | Ownership: Geneoscopy:Stock Options;Droplet Biosciences:Ownership Equity;LiquidCell Dx Inc.:Ownership Equity;Patent filings related to cancer biomarkers:Copyright | Leadership: Translational Lung Cancer Research:Editorial Board;Molecular Diagnosis & Therapy:Editorial Board;NIH Liquid Biopsy Interest Group:Co-Chair;Siteman Cancer Center ctDNA Working Group:Leader;NSCLC Multidisciplinary Advisory Council:Member of the advisory council###Washington University in St. Louis###Presenter: – Washington University in St. Louis
### 8:20 AM – 8:27 AM PT
135 - Proteogenomic Analysis of Human Uterine Cervical Cancer (UCC) Reveals Treatment-Resistant Subtypes of UCCLocation: Room 4Presenter: – National Cancer Center
Joo-Young Kim, MD, PhD – National Cancer Center ### 1971976###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###National Cancer Center###Presenter: – National Cancer Center
### 8:30 AM – 8:37 AM PT
136 - Prognostic Significance of Pretreatment Immune Cell Infiltration in Muscle Invasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712Location: Room 4Presenter: – Rutgers University
Matthew Deek, MD – Rutgers University ### 524839###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Rutgers University###Presenter: – Rutgers University
### 8:40 AM – 8:47 AM PT
137 - Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLCLocation: Room 4Presenter: – University of Chicago Pritzker School of Medicine
Liam Spurr, BS – University of Chicago Pritzker School of Medicine ### 1971977###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Chicago Pritzker School of Medicine###Presenter: – University of Chicago Pritzker School of Medicine
### 8:50 AM – 8:57 AM PT
138 - Comprehensive Genomic Analysis Stratified by KRAS Status in Patients with Pancreatic Adenocarcinoma and Its Prognostic SignificanceLocation: Room 4Presenter: – Rutgers Cancer Institute of New Jersey
Jongmyung Kim, MD, PhD – Rutgers Cancer Institute of New Jersey ### 1971978###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Rutgers Cancer Institute of New Jersey###Presenter: – Rutgers Cancer Institute of New Jersey
### 8:05 AM – 8:10 AM PT
1024 - Synthetic MRI-Assisted and Self-Supervised Adaptive Segmentation of Organs-at-Risk (OARs) in MRI-Based Radiation TherapyLocation: Room 8Presenter: – The Institute of Cancer Research
Reza Kalantar, PhD, MS, BS – The Institute of Cancer Research ### 1972045###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The Institute of Cancer Research###Presenter: – The Institute of Cancer Research
### 8:10 AM – 8:15 AM PT
1026 - Crowdsourcing Deep Learning Algorithms to Automatically Contour GI Luminal Organs on Serial MRIsLocation: Room 8Presenter: – University of Calgary
Sangjune Lee, MD, MS, BS, FRCPC DABR – University of Calgary ### 537913###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Calgary###Presenter: – University of Calgary
### 8:15 AM – 8:20 AM PT
1028 - Contouring Analysis on Synthetic Contrast-Enhanced MR from GRMM-GAN and Implications on MR-Guide Radiation TherapyLocation: Room 8Presenter: – University of California San Francisco
Wensha Yang, PhD – University of California San Francisco ### 538240###Presenter###Disclosures: Employment: University of California, San Francisco:Associate Professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of California San Francisco###Presenter: – University of California San Francisco
### 8:20 AM – 8:25 AM PT
1030 - Deep Learning-Based Pipeline for Automatic Identification of Intestinal Regenerating Crypts in Mouse Histological ImagesLocation: Room 8Presenter: – University of Washington
Jie Fu, PhD – University of Washington ### 746641###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Washington###Presenter: – University of Washington
### 8:25 AM – 8:30 AM PT
1032 - Towards Automated Dosimetric Analysis of the Bladder Trigone: Deep-Learning-Based Joint Segmentation and Landmark LocalizationLocation: Room 8
Hengjie Liu, BS – UCLA ### 1972047###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UCLA###Presenter: – UCLA
### 8:30 AM – 8:35 AM PT
1034 - Organ Specific Deep Learning-Based Correction of Inaccurate Auto-Segmentation on Abdominal MRILocation: Room 8Presenter: – Medical College of Wisconsin
Christina Sarosiek, PhD – Medical College of Wisconsin ### 1972048###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Medical College of Wisconsin###Presenter: – Medical College of Wisconsin
### 10:50 AM – 10:55 AM PT
1048 - A Prospective Study Evaluating Sexual Health Outcomes in Patients Undergoing (Chemo)Radiation (CRT/RT) for Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC)Location: Room 7Presenter: – Princess Alexandra Hospital
Lachlan Joseph McDowell, MB, BS, MBBS, FRANZCR – Princess Alexandra Hospital ### 2010635###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Princess Alexandra Hospital###Presenter: – Princess Alexandra Hospital
### 10:55 AM – 11:00 AM PT
1050 - Patient-Reported Outcomes Evaluating the Impact of Hypo-Fractionated Palliative Quadshot Radiotherapy and Concurrent CDDP Treatment on Health-Related Quality of Life in Patients with Locally Advanced Location: Room 7Presenter: – All India Institute of Medical Sciences
Jhansi Pattanaik, MD, MBBS – All India Institute of Medical Sciences ### 1972056###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###All India Institute of Medical Sciences###Presenter: – All India Institute of Medical Sciences
### 11:00 AM – 11:05 AM PT
1052 - Hearing Outcomes in Cisplatin or Cetuximab Combined with Radiation for Patients with HPV-Associated Oropharyngeal Cancer in NRG/RTOG 1016Location: Room 7Presenter: – Medical College of Wisconsin
Christina Runge, PhD – Medical College of Wisconsin ### 1972057###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Medical College of Wisconsin###Presenter: – Medical College of Wisconsin
### 11:05 AM – 11:10 AM PT
1054 - Natural History and Clinical/Dosimetric Determinants of Osteoradionecrosis in a Large Cohort of Head and Neck Cancer Following Curative Radiotherapy: Debunking the Myth of Decreased Rates of OsteoradiLocation: Room 7Presenter: – MD Anderson Cancer Center
Abdallah Mohamed, MD, PhD – MD Anderson Cancer Center ### 525110###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 11:10 AM – 11:15 AM PT
1056 - Long-Term Outcomes of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell CarcinomaLocation: Room 7Presenter: – University of North Carolina at Chapel Hill
Ryan Morse, MD – University of North Carolina at Chapel Hill ### 537838###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of North Carolina at Chapel Hill###Presenter: – University of North Carolina at Chapel Hill
### 11:15 AM – 11:20 AM PT
1058 - Brachial Plexus Tolerance to Standard Fractionation Re-Irradiation: The Ohio State University ExperienceLocation: Room 7Presenter: – The James Cancer Hospital & Solove Research Institute
Khaled Dibs, MD – The James Cancer Hospital & Solove Research Institute ### 1972058###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The James Cancer Hospital & Solove Research Institute###Presenter: – The James Cancer Hospital & Solove Research Institute
### 10:55 AM – 11:00 AM PT
1038 - TFAM Modulates Cardiomyocytes Pyroptosis Induced by Ionizing Radiation through mtDNA/TLR9/NF-kB PathwayLocation: Room 8Presenter: – Shandong Cancer Hospital and Institute
Guoxin Cai, MD – Shandong Cancer Hospital and Institute ### 747344###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Shandong Cancer Hospital and Institute###Presenter: – Shandong Cancer Hospital and Institute
### 11:00 AM – 11:05 AM PT
1042 - Single-Cell RNA Sequencing Reveals a Subset of cMAS can Aggravate RIHD through CXCL1-CXCR2 AxisLocation: Room 8
Dawei Chen, MD, MB ### 2029570###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 11:05 AM – 11:10 AM PT
1044 - HPK1 Inhibition Enhances HXRT Anti-Tumor Immune Response by Regulating RGS16 to Restore Functionality in Tumor-Infiltrating Exhausted CD8+T CellsLocation: Room 8
Dawei Chen, MD, MB ### 2029570###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 11:10 AM – 11:15 AM PT
1046 - Bifunctional Role of Monocyte Subsets in Modulating Radiotherapy Combined Intra-Tumor aCD40 Agonist Induced Abscopal EffectLocation: Room 8
Yue Zhao, MD, PhD – China ### 1975191###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###China###Presenter: – China
### 10:45 AM – 10:52 AM PT
151 - Dosimetry Reconstruction in Radiopharmaceutical Therapy Using a Sparse Network of External ?-SensorsLocation: Room 30 A/B/CPresenter: – University of California, Berkeley
Rahul Lall, BS – University of California, Berkeley ### 1971979###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of California, Berkeley###Presenter: – University of California, Berkeley
### 10:55 AM – 11:02 AM PT
152 - Long-Term Results of a Multi-Institutional Study of Dynamic Tumor Tracking-Stereotactic Body Radiotherapy for Lung TumorsLocation: Room 30 A/B/CPresenter: – Kindai University Faculty of Medicine
Yukinori Matsuo, MD, PhD – Kindai University Faculty of Medicine ### 1971980###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Kindai University Faculty of Medicine###Presenter: – Kindai University Faculty of Medicine
### 11:05 AM – 11:12 AM PT
153 - Assessment of Dynamic Contrast Enhanced (DCE) MRI for Detection of Radiotherapy Induced Alteration in Mandibular VasculatureLocation: Room 30 A/B/CPresenter: – MD Anderson Cancer Center
Moamen Abobakr, MD – MD Anderson Cancer Center ### 1971981###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 11:15 AM – 11:22 AM PT
154 - Theranostic Nanoparticle Uptake in Patient Brain Tumors as Quantified by MP2RAGE T1 MappingLocation: Room 30 A/B/CPresenter: – Massachusetts General Brigham
Stephanie Bennett, PhD – Massachusetts General Brigham ### 1971982###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Massachusetts General Brigham###Presenter: – Massachusetts General Brigham
### 11:25 AM – 11:32 AM PT
155 - The Microvascular Health Status Predicts Radio-Induced Acute Toxicities in Breast, Prostate and Head and Neck Cancer PatientsLocation: Room 30 A/B/CPresenter: – Fondazione IRCCS - Istituto Nazionale dei Tumori
Tiziana Rancati, MS – Fondazione IRCCS - Istituto Nazionale dei Tumori ### 747410###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Fondazione IRCCS - Istituto Nazionale dei Tumori###Presenter: – Fondazione IRCCS - Istituto Nazionale dei Tumori
### 11:35 AM – 11:42 AM PT
156 - Auto-Correction for Inaccurate Auto-Segmentation of Abdominal MRI by Combining Deep Learning and Active Contour MethodLocation: Room 30 A/B/CPresenter: – Medical College of Wisconsin
Mohammad Zarenia, PhD – Medical College of Wisconsin ### 1971983###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Medical College of Wisconsin###Presenter: – Medical College of Wisconsin
### 10:45 AM – 10:52 AM PT
145 - Prospective Phase II Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed By Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Location: Room 6 D/EPresenter: – Southeast Radiation Oncology Group PA
John Heinzerling, MD, OCN – Southeast Radiation Oncology Group PA ### 524541###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Southeast Radiation Oncology Group PA###Presenter: – Southeast Radiation Oncology Group PA
### 10:55 AM – 11:02 AM PT
146 - Adaptive Radiotherapy Guided by PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase II Randomized StudyLocation: Room 6 D/EPresenter: – Shanghai Pulmonary Hospital
Yaoyao Zhu, MS, RT – Shanghai Pulmonary Hospital ### 2065895###Presenter######Shanghai Pulmonary Hospital###Presenter: – Shanghai Pulmonary Hospital
### 10:55 AM – 11:02 AM PT
146 - Adaptive Radiotherapy Guided by PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase II Randomized StudyLocation: Room 6 D/EPresenter: – Shanghai Pulmonary Hospital
Yaping Xu, PhD – Shanghai Pulmonary Hospital ### 535769###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Shanghai Pulmonary Hospital###Presenter: – Shanghai Pulmonary Hospital
### 11:05 AM – 11:12 AM PT
147 - Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD): Primary Analysis of a Phase II TrialLocation: Room 6 D/EPresenter: – London Health Sciences Centre
David Palma, MD, PhD – London Health Sciences Centre ### 524579###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###London Health Sciences Centre###Presenter: – London Health Sciences Centre
### 11:15 AM – 11:22 AM PT
148 - Dosimetric Impact of Systematic Mediastinal Staging via Endobronchial Ultrasound for Patients with Locally Advanced Lung Cancer: The SEISMIC TrialLocation: Room 6 D/EPresenter: – Peter MacCallum Cancer Centre
Shankar Siva, PhD, MBBS, FRANZCR – Peter MacCallum Cancer Centre ### 524764###Presenter###Disclosures: Employment: Peter MacCallum Cancer Centre:Radiation Oncologist:Employee | Compensation: AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Education Meeting Faculty, Remuneration Other-End Date: present ;Varian Medical Systems: Education Meeting Faculty, Research Grants, Research Funding, Research Salary Support, Remuneration Other-End Date: present ;Reflexion Medical Systems: Research Grants, Research Funding, Research Salary Support, Remuneration Other-End Date: 2022 | Ownership: none | Leadership: ART committee of IASLC:committee member;Radiosurgery Society (RSS):Board Directoy###Peter MacCallum Cancer Centre###Presenter: – Peter MacCallum Cancer Centre
### 11:25 AM – 11:32 AM PT
149 - Circulating Tumor DNA for Early Risk Stratification of Oligometastatic Lung CancerLocation: Room 6 D/EPresenter: – Washington University in St. Louis
Aadel Chaudhuri, MD, PhD – Washington University in St. Louis ### 524821###Presenter###Disclosures: Employment: Washington University in St. Louis:Assistant Professor:Employee | Compensation: Roche: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria, Travel Expenses, Compensation Payment-End Date: Present ;Tempus Labs: Consultant, Grant Research Funding, Compensation Payment-End Date: Present ;Geneoscopy: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Remuneration Other-End Date: Present ;Illumina: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: Present ;Daiichi Sankyo: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: Present ;AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: Present ;AlphaSights: Consultant, Compensation Payment-End Date: Present ;DeciBio: Consultant, Compensation Payment-End Date: Present ;Guidepoint: Consultant, Compensation Payment-End Date: Present ;Dava Oncology: Education Meeting Faculty, Honoraria-End Date: 8/2021 ;NuProbe: Consultant, Compensation Payment-End Date: 11/2021 | Ownership: Geneoscopy:Stock Options;Droplet Biosciences:Ownership Equity;LiquidCell Dx Inc.:Ownership Equity;Patent filings related to cancer biomarkers:Copyright | Leadership: Translational Lung Cancer Research:Editorial Board;Molecular Diagnosis & Therapy:Editorial Board;NIH Liquid Biopsy Interest Group:Co-Chair;Siteman Cancer Center ctDNA Working Group:Leader;NSCLC Multidisciplinary Advisory Council:Member of the advisory council###Washington University in St. Louis###Presenter: – Washington University in St. Louis
### 11:35 AM – 11:42 AM PT
150 - Residual ctDNA Detection Predicts Benefit From Definitive Chemoradiotherapy and Immune Checkpoint Inhibitors in Locally Advanced NSCLCLocation: Room 6 D/EPresenter: – Chinese Academy of Medical Sciences and Peking Union Medical College
Yu Wang, MD – Chinese Academy of Medical Sciences and Peking Union Medical College ### 1971999###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Chinese Academy of Medical Sciences and Peking Union Medical College###Presenter: – Chinese Academy of Medical Sciences and Peking Union Medical College
### 11:45 AM – 11:55 AM PT
DiscussantLocation: Room 6 D/EDiscussant: – University of Pennsvania Radiation Oncology
Jeffrey Bradley, MD, FASTRO – University of Pennsvania Radiation Oncology ### 524838###Discussant###Disclosures: Employment: Emory School of Medicine:Professor:Employee | Compensation: Mevion Medical Systems, Inc: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Uncompensated-End Date: to present ;Varian, Inc: Consultant, Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: to present ;Genentech, Inc: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: to present ;AstraZeneca, Inc: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Travel Expenses-End Date: to present | Ownership: none | Leadership: none###University of Pennsvania Radiation Oncology###Discussant: – University of Pennsvania Radiation Oncology
### 10:45 AM – 10:52 AM PT
139 - Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy: NRG Oncology/RTOG 0534 SPPORTLocation: Room 6 C/FPresenter: – Nell Hodgson Woodruff School of Nursing
Deborah Bruner, PhD, RN, FAAN – Nell Hodgson Woodruff School of Nursing ### 524661###Presenter###Disclosures: Employment: Emory University:Senior Vice President for Research:Employee | Compensation: ASTRO: Other, Honoraria-End Date: present ;Center for Global Health Initiative - Atlanta GA: Other, Uncompensated-End Date: present ;Flatiron Health: Consultant, Compensation Payment-End Date: 05/21/2022 ;Memorial Sloan Kettering Cancer Center: Other, Honoraria-End Date: 01/18/2022 ;National Cancer Institute: Other, Travel Expenses-End Date: present ;NRG Oncology Executive Advisory Board: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Travel Expenses, Remuneration Other-End Date: present ;Oncology Nursing Society: Other, Honoraria-End Date: 04/29/2021 ;PROTEUS Consortium: Other, Uncompensated-End Date: present ;U.S. Global Leadership Coalition: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Other, Uncompensated-End Date: present ;Wilmont Cancer Center: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: present | Ownership: Abbvie:Other;Bristol-Myers Squibb:Other;GlaxoSmithKline:Other;Johnson & Johnson:Other;Pfizer:Other;Proctor & Gamble:Other;Stryker Corp.:Other;Walgreens Boots Alliance:Other | Leadership: none###Nell Hodgson Woodruff School of Nursing###Presenter: – Nell Hodgson Woodruff School of Nursing
### 10:45 AM – 12:00 PM PT
DiscussantLocation: Room 6 C/FDiscussant: – University of Montreal Hospital (CHUM)
Cynthia Menard, MD – University of Montreal Hospital (CHUM) ### 524471###Discussant###Disclosures: Employment: CHUM:Department Chief:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of Montreal Hospital (CHUM)###Discussant: – University of Montreal Hospital (CHUM)
### 10:55 AM – 11:02 AM PT
140 - Final Analysis of a Phase III Controlled Randomized Study of Stereotactic Body Proton Therapy or Conventionally Fractionated Proton Therapy for Early Prostate Cancer: PCG GU002Location: Room 6 C/FPresenter: – Mayo Clinic Arizona
Diego Toesca, MD – Mayo Clinic Arizona ### 537606###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Mayo Clinic Arizona###Presenter: – Mayo Clinic Arizona
### 11:05 AM – 11:12 AM PT
141 - Conventional vs. Hypo-Fractionated, Radiotherapy for High-Risk Prostate Cancer (PCS5), Randomized, Non-Inferiority, Phase 3 Trial: Posthoc Analysis of IMRT vs. 3D-CRT Radiation Therapy Associated ToxiLocation: Room 6 C/FPresenter: – McGill University Health Centre
Constanza Martinez, MD, PhD – McGill University Health Centre ### 1972566###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###McGill University Health Centre###Presenter: – McGill University Health Centre
### 11:15 AM – 11:22 AM PT
142 - Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate Location: Room 6 C/FPresenter: – McGill University
Tamim Niazi, MD – McGill University ### 524755###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###McGill University###Presenter: – McGill University
### 11:25 AM – 11:32 AM PT
143 - Progression-Directed Therapy in Oligoprogressive Castration-Refractory Prostate Cancer: Results of the Prospective Single-Arm Phase II MEDCARE TrialLocation: Room 6 C/F
Gert De Meerleer, MD, PhD – UZ Leuven ### 2086546###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UZ Leuven###Presenter: – UZ Leuven
### 11:35 AM – 11:42 AM PT
144 - The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B StudyLocation: Room 6 C/FPresenter: – Royal Marsden NHS Foundation Trust
Ragu Ratnakumaran, MBBS – Royal Marsden NHS Foundation Trust ### 1972022###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Royal Marsden NHS Foundation Trust###Presenter: – Royal Marsden NHS Foundation Trust
### 1:30 PM – 1:40 PM PT
LBA 04 - Primary Endpoint Results of NRG CC003: Phase IIR/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC)Location: Ballroom 20Presenter: – Northwestern Medicine Cancer Center Warrenville and Proton Center
Vinai Gondi, MD – Northwestern Medicine Cancer Center Warrenville and Proton Center ### 524455###Presenter###Disclosures: Employment: Radiation Oncology Consultants, LLC:Physician Partner:Partner | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###Northwestern Medicine Cancer Center Warrenville and Proton Center###Presenter: – Northwestern Medicine Cancer Center Warrenville and Proton Center
### 1:40 PM – 1:50 PM PT
DiscussantLocation: Ballroom 20Discussant: – MD Anderson Cancer Center
Debra Yeboa, MD – MD Anderson Cancer Center ### 747057###Discussant###Disclosures: Employment: Univ of Texas MD Anderson Cancer Center:Associate Professor:Employee | Compensation: Practical Radiation Oncology Journal: Other, Uncompensated-End Date: present ;Robert Wood Johnson: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: present ;Brockman Foundation/ Medical research Grant: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: present ;MD Anderson Institutional Research Grant Funding: Grant Research Funding-End Date: to present | Ownership: none | Leadership: Society of Neuro-Oncology:Radiation Sciences Co-chair;Radiosurgery Society (RSS):Annual Planning Committee member & MD Anderson liason###MD Anderson Cancer Center###Discussant: – MD Anderson Cancer Center
### 1:50 PM – 2:00 PM PT
1 - High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 TrialLocation: Ballroom 20Presenter: – Peking University Cancer Hospital and Institute
Jiayi Yu, PhD – Peking University Cancer Hospital and Institute ### 2082532###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Peking University Cancer Hospital and Institute###Presenter: – Peking University Cancer Hospital and Institute
### 2:00 PM – 2:10 PM PT
DiscussantLocation: Ballroom 20Discussant: – Winship Cancer Institute of Emory University
Kristin Higgins, MD – Winship Cancer Institute of Emory University ### 525180###Discussant###Disclosures: Employment: Emory Healthcare:Medical Director:Employee | Compensation: Astra Zeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant-End Date: to present ;RefleXion Medical: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: to present ;Janssen Pharmaceuticals: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant, Compensation Payment-End Date: to present ;Genentech: Consultant-End Date: to present ;Jazz Pharmaceuticals: Research Grants, Research Funding, Research Salary Support, Salary Support-End Date: to present | Ownership: none | Leadership: NRG Oncology:General DIrector###Winship Cancer Institute of Emory University###Discussant: – Winship Cancer Institute of Emory University
### 2:10 PM – 2:20 PM PT
LBA 03 - 5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated ExteLocation: Ballroom 20Presenter: – The Royal Marsden NHS Foundation Trust
Nicholas van As, MD, MB – The Royal Marsden NHS Foundation Trust ### 2105488###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The Royal Marsden NHS Foundation Trust###Presenter: – The Royal Marsden NHS Foundation Trust
### 2:20 PM – 2:30 PM PT
DiscussantLocation: Ballroom 20Discussant: – Princess Margaret Cancer Centre
Alejandro Berlin, MD, MS – Princess Margaret Cancer Centre ### 538171###Discussant###Disclosures: Employment: University Health Network:Radiation Oncologist, Clinician-Scientist:Employee | Compensation: NRG Oncology: Research Grants, Research Funding, Research Salary Support, Uncompensated-End Date: to present | Ownership: none | Leadership: none###Princess Margaret Cancer Centre###Discussant: – Princess Margaret Cancer Centre
### 2:30 PM – 2:40 PM PT
LBA 01 - Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920Location: Ballroom 20Presenter: – Penn State Hershey Medical Center
Mitchell Machtay, MD, FASTRO – Penn State Hershey Medical Center ### 516024###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Penn State Hershey Medical Center###Presenter: – Penn State Hershey Medical Center
### 2:40 PM – 2:50 PM PT
LBA 02 - Randomized Controlled Trial of Hypofractionated vs. Normo-fractionated Accelerated Radiation Therapy with or without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO)Location: Ballroom 20Presenter: – University of Maryland School of Medicine
Soren Bentzen, DSc, PhD, FASTRO – University of Maryland School of Medicine ### 524521###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Maryland School of Medicine###Presenter: – University of Maryland School of Medicine
### 2:50 PM – 3:00 PM PT
DiscussantLocation: Ballroom 20Discussant: – Baylor College of Medicine
Christina Chapman, MD, MS – Baylor College of Medicine ### 535694###Discussant###Disclosures: Employment: none | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###Baylor College of Medicine###Discussant: – Baylor College of Medicine
### 3:00 PM – 3:07 PM PT
157 - Peripheral T-Cell Priming and Micrometastatic Disease Control with Metastasis-Directed Therapy: Multidimensional Immunogenomic Profiling of Oligometastatic Prostate Cancer in the EXTEND TrialLocation: Room 6 D/EPresenter: – University of Texas MD Anderson Cancer Center
Alexander Sherry, MD – University of Texas MD Anderson Cancer Center ### 747082###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Texas MD Anderson Cancer Center###Presenter: – University of Texas MD Anderson Cancer Center
### 3:10 PM – 3:17 PM PT
158 - Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate CancerLocation: Room 6 D/EPresenter: – The Mayo Clinic
Ryan Phillips, MD, PhD – The Mayo Clinic ### 525253###Presenter###Disclosures: Employment: The Mayo Clinic:Assistant Professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###The Mayo Clinic###Presenter: – The Mayo Clinic
### 3:20 PM – 3:27 PM PT
159 - Cross-Comparison Individual Patient Level Analysis of Three Gene Expression Signatures in Localized Prostate in over 50,000 MenLocation: Room 6 D/EPresenter: – Case Western Reserve University/University Hospitals Cleveland Medical Center
Angela Jia, MD, PhD – Case Western Reserve University/University Hospitals Cleveland Medical Center ### 850161###Presenter###Disclosures: Employment: University Hospitals, Seidman Cancer Center, Case Western Reserve University:Radiation Oncologist, Assistant Professor in Radiation Oncology:Employee | Compensation: Myovant: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria, Travel Expenses-End Date: 12/2022 | Ownership: none | Leadership: none###Case Western Reserve University/University Hospitals Cleveland Medical Center###Presenter: – Case Western Reserve University/University Hospitals Cleveland Medical Center
### 3:30 PM – 3:37 PM PT
160 - Detection Rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence at PSA Levels <1 ng/mL: Data from the Phase 3 SPOTLIGHT StudyLocation: Room 6 D/EPresenter: – Emory University
Ashesh Jani, MD, FASTRO – Emory University ### 524753###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Emory University###Presenter: – Emory University
### 3:40 PM – 3:47 PM PT
161 - PSMA-Positive Extracellular Vesicles Predict Disease Recurrence in Oligometastatic Castration-Sensitive Prostate Cancer Treated with Stereotactic Ablative Radiotherapy: Analysis of the ORIOLE trialLocation: Room 6 D/E
Edlira Horjeti, MD, MBBS – Mayo Clinic ### 1971984###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Mayo Clinic###Presenter: – Mayo Clinic
### 3:50 PM – 4:00 PM PT
DiscussantLocation: Room 6 D/EDiscussant: – MD Anderson Cancer Center
Osama Mohamad, MD, PhD – MD Anderson Cancer Center ### 525386###Discussant###Disclosures: Employment: Md Anderson cancer center, houston:Assistant professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###MD Anderson Cancer Center###Discussant: – MD Anderson Cancer Center
### 3:00 PM – 3:07 PM PT
173 - Combination of BET Inhibition with Radiation Induces Anti-Tumor Immune Response in Pre-Clinical Models of ER-Positive Breast CancerLocation: Room 30 D/EPresenter: – UT Southwestern Medical Center at Dallas
Prasanna Alluri, MD, PhD – UT Southwestern Medical Center at Dallas ### 537644###Presenter###Disclosures: Employment: UT Southwestern Medical Center:Assistant Professor:Employee | Compensation: Department of Defense: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: Present ;METAvivor: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 05/31/2025 | Ownership: none | Leadership: UT Southwestern Breast Center:Member, Breast Program Leadership Committee;UT Southwestern Breast Center:Member###UT Southwestern Medical Center at Dallas###Presenter: – UT Southwestern Medical Center at Dallas
### 3:10 PM – 3:17 PM PT
174 - CRISPR-Based Epigenome Editing and Genome Wide Screening Define Mediators of Chemotherapy Response in GlioblastomaLocation: Room 30 D/E
S. John Liu, MD, PhD – UCSF ### 747161###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UCSF###Presenter: – UCSF
### 3:20 PM – 3:27 PM PT
175 - In Silico Discovery and Investigation of Novel Small Molecules Targeting PSMA7 for the Treatment of GBMLocation: Room 30 D/EPresenter: – The Ohio State University
Christian Showalter, PhD – The Ohio State University ### 1971985###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###The Ohio State University###Presenter: – The Ohio State University
### 3:30 PM – 3:37 PM PT
176 - Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant TherapyLocation: Room 30 D/EPresenter: – UAMS Radiation Oncology
Anam Kesaria, MD – UAMS Radiation Oncology ### 1971986###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UAMS Radiation Oncology###Presenter: – UAMS Radiation Oncology
### 3:40 PM – 3:47 PM PT
177 - Targeting Non-Kinase Function of CDK6 to Overcome CDK4/6 Inhibitor ResistanceLocation: Room 30 D/EPresenter: – UT Southwestern Medical Center at Dallas
Prasanna Alluri, MD, PhD – UT Southwestern Medical Center at Dallas ### 537644###Presenter###Disclosures: Employment: UT Southwestern Medical Center:Assistant Professor:Employee | Compensation: Department of Defense: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: Present ;METAvivor: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 05/31/2025 | Ownership: none | Leadership: UT Southwestern Breast Center:Member, Breast Program Leadership Committee;UT Southwestern Breast Center:Member###UT Southwestern Medical Center at Dallas###Presenter: – UT Southwestern Medical Center at Dallas
### 3:50 PM – 3:57 PM PT
178 - Nanobody-Based ImmunoPET for Hepatocellular CarcinomaLocation: Room 30 D/EPresenter: – National Cancer Institute
Stanley Fayn, BS – National Cancer Institute ### 1971987###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###National Cancer Institute###Presenter: – National Cancer Institute
### 3:00 PM – 3:07 PM PT
168 - Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer: Primary Endpoint Results of the SAVE Randomized Clinical TrialLocation: Room 31Presenter: – University of Utah Huntsman Cancer Institute
Gita Suneja, MD, MS – University of Utah Huntsman Cancer Institute ### 552886###Presenter###Disclosures: Employment: University of Utah:Associate Professor:Employee | Compensation: NIH/NCI: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 9/2023 ;American Brachytherapy Society: Education Meeting Faculty, Uncompensated-End Date: 2/2022 ;American College of Radiation Oncology: Education Meeting Faculty, Travel Expenses-End Date: 3/2023 ;Binaytara Foundation: Education Meeting Faculty, Travel Expenses-End Date: 4/2023 | Ownership: none | Leadership: Radiation Oncology Institute:Vice-Chair###University of Utah Huntsman Cancer Institute###Presenter: – University of Utah Huntsman Cancer Institute
### 3:10 PM – 3:17 PM PT
169 - Toripalimab Combined with Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients: Early Results of Safety and FeasibilityLocation: Room 31
Dan Ou, MD ### 1975175###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 3:20 PM – 3:27 PM PT
170 - Evaluating the Effects of Bone Marrow Sparing Radiotherapy on Acute Hematologic Toxicity for Patients with Locoregionally Advanced Cervical Cancer: A Prospective Phase II Randomized Controlled TrialLocation: Room 31Presenter: – West China Second University Hospital
Wen Li, PhD candidate – West China Second University Hospital ### 1975176###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###West China Second University Hospital###Presenter: – West China Second University Hospital
### 3:30 PM – 3:37 PM PT
171 - HYPOCx-iRex (TCTR20210812003) A Phase II RCT: 44Gy/20F VS 45Gy/25F CCRT in Cervical Cancer - 6-mo Post-RT UpdateLocation: Room 31Presenter: – Siriraj Hospital Mahidol University
Tissana Prasartseree, MD – Siriraj Hospital Mahidol University ### 1975177###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Siriraj Hospital Mahidol University###Presenter: – Siriraj Hospital Mahidol University
### 3:40 PM – 3:47 PM PT
172 - Multiple Sessions vs. Single Session Image-Based Intracavitary Brachytherapy for Locally Advanced Cervical Cancer - A Randomized Control TrialLocation: Room 31Presenter: – AIIMS New Delhi
Daya Nand Sharma, MD, PhD – AIIMS New Delhi ### 2143441###Presenter######AIIMS New Delhi###Presenter: – AIIMS New Delhi
### 3:48 PM – 3:58 PM PT
DiscussantLocation: Room 31Discussant: – University of Colorado Anschutz Medical Campus
Katherine Tzou, MD – University of Colorado Anschutz Medical Campus ### 1975178###Discussant###Disclosures: Employment: University of Colorado:Associate Professor of Radiation Oncology:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of Colorado Anschutz Medical Campus###Discussant: – University of Colorado Anschutz Medical Campus
### 3:00 PM – 3:07 PM PT
162 - Radiochemical Oxygen Depletion Depends on Chemical Environment and Dose-Rate: Implications for FLASH EffectLocation: Room 30 A/B/CPresenter: – University of Pennsylvania
Rodney Wiersma, PhD – University of Pennsylvania ### 1972011###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Pennsylvania###Presenter: – University of Pennsylvania
### 3:10 PM – 3:17 PM PT
163 - A Novel Planning and Delivery Technology: Dose, Dose Rate and Linear Energy Transfer(LET) Optimization Based on Spot-Scanning Proton Arc Therapy FLASH (SPLASHLET)Location: Room 30 A/B/CPresenter: – Beaumont Health System
Gang Liu, PhD – Beaumont Health System ### 1972012###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Beaumont Health System###Presenter: – Beaumont Health System
### 3:10 PM – 3:17 PM PT
163 - A Novel Planning and Delivery Technology: Dose, Dose Rate and Linear Energy Transfer(LET) Optimization Based on Spot-Scanning Proton Arc Therapy FLASH (SPLASHLET)Location: Room 30 A/B/CPresenter: – William Beaumont Hospital
Xiaoqiang Li, PhD – William Beaumont Hospital ### 746630###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###William Beaumont Hospital###Presenter: – William Beaumont Hospital
### 3:20 PM – 3:27 PM PT
164 - An Effective Dose Rate Optimization Algorithm for Efficient Conventional-Dose-Rate Proton Therapy and Ultra-High-Dose-Rate FLASH Proton TherapyLocation: Room 30 A/B/CPresenter: – University of Kansas Medical Center
Yuting Lin, PhD – University of Kansas Medical Center ### 2122124###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Kansas Medical Center###Presenter: – University of Kansas Medical Center
### 3:30 PM – 3:37 PM PT
165 - Towards Clinical Proton Minibeam Radiation Therapy (pMBRT): Development of Clinical pMBRT System Prototype and pMBRT-Specific Treatment Planning MethodLocation: Room 30 A/B/CPresenter: – University of Kansas Medical Center
Hao Gao, PhD – University of Kansas Medical Center ### 746653###Presenter###Disclosures: Employment: University of Kansas:Associate Professor:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: none###University of Kansas Medical Center###Presenter: – University of Kansas Medical Center
### 3:40 PM – 3:47 PM PT
166 - Towards Clinical Translation of Microbeam Radiation Therapy (MRT) with a Compact SourceLocation: Room 30 A/B/C
Stefan Bartzsch, PhD ### 1973077###Presenter#########Presenter:
### 3:50 PM – 3:57 PM PT
167 - Spot Scanning Proton Therapy for Pregnant Patients with Brain and Head and Neck TumorsLocation: Room 30 A/B/C
Justine Dupere, PhD – Mayo Clinic ### 1972015###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Mayo Clinic###Presenter: – Mayo Clinic
### 3:05 PM – 3:10 PM PT
1060 - Implementation Outcomes of Strategies to Promote Short-Course Radiation for Nonspine Bone Metastases in an Academic-Community Partnership: Survey Results from the ALIGNMENT TrialLocation: Room 8Presenter: – Memorial Sloan Kettering Cancer Center
Patricia Santos, MD, MS – Memorial Sloan Kettering Cancer Center ### 1972063###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 3:15 PM – 3:20 PM PT
1064 - Patient and Caregivers Opinions on Receiving Radiology Results before Oncologist AppointmentsLocation: Room 8Presenter: – City of Hope National Medical Center
Nicholas Eustace, MD, PhD, BS – City of Hope National Medical Center ### 1972064###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###City of Hope National Medical Center###Presenter: – City of Hope National Medical Center
### 3:20 PM – 3:25 PM PT
1066 - Do Physician Patient Sharing Networks Impact Disparities in Access to Multidisciplinary Cancer Consultation for Early Stage Lung Cancer? A SEER-Medicare Network AnalysisLocation: Room 8Presenter: – Dartmouth-Hitchcock Medical Center
Nirav Kapadia, MD, MS – Dartmouth-Hitchcock Medical Center ### 1961860###Presenter###Disclosures: Employment: Dartmouth Health:Associate Professor of Medicine (Radiation Oncology):Employee;Alison Kapadia:Assistant Professor Emergency Medicine:Employee | Compensation: :Role Topic Description-End Date: | Ownership: none | Leadership: Northern New England Clinical Oncology Society:Treasurer; Board/Executive Committee Member###Dartmouth-Hitchcock Medical Center###Presenter: – Dartmouth-Hitchcock Medical Center
### 3:25 PM – 3:30 PM PT
1068 - Multi-Institutional Fact-Finding Study: Association between Geriatric Assessment and Reduction in Intensity of Radiotherapy for Elderly Cancer Patients without MetastasisLocation: Room 8Presenter: – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Keiko Murofushi, MD, PhD – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital ### 1972065###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital###Presenter: – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
### 3:30 PM – 3:35 PM PT
1070 - Radiotherapy Access and Treatment in Rwanda: Demographics and Clinical Characteristics of Cervical Cancer PatientsLocation: Room 8Presenter: – Albert Einstein College of Medicine
Timothy Davis, BS – Albert Einstein College of Medicine ### 1972066###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Albert Einstein College of Medicine###Presenter: – Albert Einstein College of Medicine
### 5:00 PM – 5:07 PM PT
179 - Is it the Type of Axillary Surgery or the Number of Removed Lymph Nodes That Increases the Risk of Breast Cancer Related Lymphedema (BCRL)? Results from a Prospective Screening TrialLocation: Room 6 C/FPresenter: – Massachusetts General Hospital
George Naoum, MD, MS – Massachusetts General Hospital ### 535714###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Massachusetts General Hospital###Presenter: – Massachusetts General Hospital
### 5:09 PM – 5:16 PM PT
180 - Increased Complication Rates with Proton Therapy in Breast Cancer Patients with Immediate, Implant-Based Reconstruction: Single-Institution Comparative Effectiveness AnalysisLocation: Room 6 C/FPresenter: – Massachusetts General Hospital
Alphonse Taghian, MD, PhD, FASTRO – Massachusetts General Hospital ### 524513###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Massachusetts General Hospital###Presenter: – Massachusetts General Hospital
### 5:18 PM – 5:25 PM PT
181 - Risk of Radiation-Associated Secondary Malignancies Among Patients with Breast Cancer Harboring TP53 Germline VariantsLocation: Room 6 C/FPresenter: – Memorial Sloan Kettering Cancer Center
Gustav Cederquist, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1972756###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 5:27 PM – 5:34 PM PT
182 - Early Results of the French Multicenter, Randomized SHARE Trial Comparing Whole Breast Irradiation vs. Accelerated Partial Breast Irradiation in Postmenopausal Women with Early-Stage Breast CancerLocation: Room 6 C/FPresenter: – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII
Yazid Belkacemi, MD, PhD – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII ### 525052###Presenter######Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII###Presenter: – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII
### 5:36 PM – 5:43 PM PT
183 - Comparison between Pre-Pectoral and Post-Pectoral Implant Reconstruction and Different Radiation Modalities on Breast Reconstruction ComplicationsLocation: Room 6 C/FPresenter: – Massachusetts General Hospital
George Naoum, MD, MS – Massachusetts General Hospital ### 535714###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Massachusetts General Hospital###Presenter: – Massachusetts General Hospital
### 5:45 PM – 5:52 PM PT
184 - Effectiveness and Toxicity of Five Fraction Prone Accelerated Partial Breast IrradiationLocation: Room 6 C/FPresenter: – NYU Grossman School of Medicine
Camille Hardy Abeloos, MD – NYU Grossman School of Medicine ### 1972367###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###NYU Grossman School of Medicine###Presenter: – NYU Grossman School of Medicine
### 5:54 PM – 5:58 PM PT
DiscussantLocation: Room 6 C/FDiscussant: – University of Colorado Denver
Rachel Rabinovitch, MD, FASTRO – University of Colorado Denver ### 524443###Discussant###Disclosures: Employment: University of Colorado Hospital:Professor:Employee | Compensation: Prelude: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Uncompensated-End Date: present | Ownership: Abbott Laboratories:Stock;Bristol-Myers Squibb:Stock;Intuitive Surgical:Stock;Pfizer:Stock;Zimmer Biomet:Stock | Leadership: none###University of Colorado Denver###Discussant: – University of Colorado Denver
### 5:54 PM – 6:00 PM PT
DiscussantLocation: Room 6 C/FDiscussant: – Johns Hopkins University
Jean Wright, MD, FASTRO – Johns Hopkins University ### 524511###Discussant###Disclosures: Employment: Johns Hopkins University:Associate Professor, Radiation Oncology:Employee;National Institutes of Health:Associate Director, NINDS:Employee | Compensation: Up To Date: Other, Compensation Payment-End Date: present ;ASTRO: Other, Honoraria-End Date: present ;Oncospace: Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Salary Support-End Date: present ;Prostate Cancer Foundation: Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Salary Support-End Date: present ;Marshall Dennehy: Consultant, Compensation Payment-End Date: 9/22/22 ;Physicians Education Resource: Education Meeting Faculty, Honoraria, Travel Expenses-End Date: 3/3/2023 ;Elsevier Journals: Other, Honoraria-End Date: present | Ownership: none | Leadership: American Board of Radiology:Oral Board Examiner;ASTRO:Chair, Clinical Affairs and Quality Committee###Johns Hopkins University###Discussant: – Johns Hopkins University
### 5:00 PM – 5:07 PM PT
191 - Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional StudyLocation: Room 31Presenter: – University of Pennsylvania Health System
Nikhil Yegya-Raman, MD – University of Pennsylvania Health System ### 538407###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Pennsylvania Health System###Presenter: – University of Pennsylvania Health System
### 5:10 PM – 5:17 PM PT
192 - Phase I Trial of Re-Priming Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-Cell (CAR-T) TherapyLocation: Room 31Presenter: – UT Southwestern Medical Center
Kiran Kumar, MD, MBA – UT Southwestern Medical Center ### 1971996###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UT Southwestern Medical Center###Presenter: – UT Southwestern Medical Center
### 5:20 PM – 5:27 PM PT
193 - Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin LymphomaLocation: Room 31Presenter: – Mayo Clinic Florida
Omran Saifi, MD – Mayo Clinic Florida ### 1971997###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Mayo Clinic Florida###Presenter: – Mayo Clinic Florida
### 5:30 PM – 5:37 PM PT
194 - Prognostic Significance of Positron Emission Tomography Delta Radiomics Following Bridging Therapy in Patients with Large B-Cell Lymphoma Undergoing CAR T-Cell TherapyLocation: Room 31Presenter: – City of Hope National Medical Center
Colton Ladbury, MD, BS – City of Hope National Medical Center ### 747995###Presenter###Disclosures: Employment: City of Hope National Medical Center:Resident Physician:Employee | Compensation: RefleXion Medical: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: Present | Ownership: none | Leadership: none###City of Hope National Medical Center###Presenter: – City of Hope National Medical Center
### 5:40 PM – 5:47 PM PT
195 - Characterization of Lymphopenia during Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Patients with Aggressive B Cell LymphomasLocation: Room 31Presenter: – MD Anderson Cancer Center
Gohar Manzar, MD, PhD – MD Anderson Cancer Center ### 537790###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###MD Anderson Cancer Center###Presenter: – MD Anderson Cancer Center
### 5:50 PM – 6:00 PM PT
DiscussantLocation: Room 31Discussant: – Yale Therapeutic Radiology
Timothy Robinson, MD, PhD – Yale Therapeutic Radiology ### 1996488###Discussant###Disclosures: Employment: Yale:Assistant Professor:Employee | Compensation: Kite Pharma: Consultant, Honoraria-End Date: Ongoing | Ownership: Duke University:Copyright;H. Lee Moffitt Cancer Center:Copyright | Leadership: Yale:Co-Leader###Yale Therapeutic Radiology###Discussant: – Yale Therapeutic Radiology
### 5:00 PM – 5:07 PM PT
185 - Real Time Volumetric MRI for MR-Guided 3D Motion Tracking via Sparse Prior-Augmented Neural Representation LearningLocation: Room 1Presenter: – Stanford University
Lianli Liu, PhD – Stanford University ### 1974818###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Stanford University###Presenter: – Stanford University
### 5:10 PM – 5:17 PM PT
186 - Heatmaps to Assess Tumor Motion Probability with MRcine in Head and Neck CancerLocation: Room 1Presenter: – Miami Cancer Institute
Yonatan Weiss, MD – Miami Cancer Institute ### 538461###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Miami Cancer Institute###Presenter: – Miami Cancer Institute
### 5:20 PM – 5:27 PM PT
187 - Principal Component Analysis to Design Planning Target Volume in Oropharyngeal CancersLocation: Room 1Presenter: – UT Southwestern Medical Center
Mona Arbab, MD, M.Ed – UT Southwestern Medical Center ### 537709###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###UT Southwestern Medical Center###Presenter: – UT Southwestern Medical Center
### 5:30 PM – 5:37 PM PT
188 - Reduction of Late Urinary Toxicity from Prostate Cancer Radiotherapy via Intrafractional MV-kV Image GuidanceLocation: Room 1Presenter: – Memorial Sloan Kettering Cancer Center
Pengpeng Zhang, PhD – Memorial Sloan Kettering Cancer Center ### 537982###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 5:40 PM – 5:47 PM PT
189 - Deep Learning-Based Single-View Fluorescence Dose Reconstruction for 3D DosimetryLocation: Room 1Presenter: – Stanford University
Yusuke Nomura, PhD – Stanford University ### 1975182###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Stanford University###Presenter: – Stanford University
### 5:50 PM – 5:57 PM PT
190 - Deep Learning-Based Automated Quality Assurance for Palliative Spinal Treatment Planning in RadiotherapyLocation: Room 1Presenter: – Brigham and Women's Hospital/Dana-Farber
Christopher Kehayias, PhD – Brigham and Women's Hospital/Dana-Farber ### 1975181###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Brigham and Women's Hospital/Dana-Farber###Presenter: – Brigham and Women's Hospital/Dana-Farber
### 5:05 PM – 5:10 PM PT
1072 - PD-L1 Inhibitors Combined with Thoracic Radiotherapy in First-Line Treatment of Extensive Stage Small Cell Lung Cancer: A Propensity Score-Matched, Real-World StudyLocation: Room 8
Jianfeng Peng, PhD ### 1972068###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none######Presenter:
### 5:10 PM – 5:15 PM PT
1074 - Progression-Free Survival As a Surrogate Endpoint of Overall Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy: Trial-Level Meta-Analysis and IndividLocation: Room 8Presenter: – Johns Hopkins University
Chen Hu, PhD – Johns Hopkins University ### 790140###Presenter###Disclosures: Employment: Johns Hopkins University:Associate Professor:Employee | Compensation: D1Med Technology Co. Ltd: Consultant, Honoraria-End Date: to present | Ownership: none | Leadership: none###Johns Hopkins University###Presenter: – Johns Hopkins University
### 5:15 PM – 5:20 PM PT
1076 - Early Stereotactic Body Radiotherapy to the Primary Lung Lesion for Patients with Advanced NSCLC Treated with First-Line Systemic TherapyLocation: Room 8Presenter: – Chongqing University Cancer Hospital
Dan Tao, MD – Chongqing University Cancer Hospital ### 1972069###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Chongqing University Cancer Hospital###Presenter: – Chongqing University Cancer Hospital
### 5:20 PM – 5:25 PM PT
1078 - Treatment Efficacy Outcomes Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Survival Analysis of a Phase IB trialLocation: Room 8Presenter: – University of Wisconsin
Brett Morris, MD, PhD – University of Wisconsin ### 525241###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###University of Wisconsin###Presenter: – University of Wisconsin
### 5:25 PM – 5:30 PM PT
1080 - Genomic Signature for Oligometastatic Disease in Non-Small Cell Lung Cancer Patients with Brain MetastasesLocation: Room 8Presenter: – Wake Forest Baptist Medical Center
Ariel Choi, MD – Wake Forest Baptist Medical Center ### 1972070###Presenter###Disclosures: Employment: none | Compensation: none | Ownership: none | Leadership: none###Wake Forest Baptist Medical Center###Presenter: – Wake Forest Baptist Medical Center
### 5:00 PM – 6:00 PM PT
2599 - Determining the Minimal Clinically Important Difference of the FACT-E to Evaluate the Change in the Quality of Life of Patients with Esophageal Cancer Treated with Curative RadiotherapyLocation: Hall B1Presenter: – IZ Statistics LLC
Isabella Zaniletti, PhD – IZ Statistics LLC ### 1972428###Presenter######IZ Statistics LLC###Presenter: – IZ Statistics LLC
###